Shareholders should contact the firm immediately as there may be limited time to enforce your rights.NEW YORK, Dec. 5, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Bioventus Inc. (NASDAQ: BVS) breached their fiduciary duties to shareholders.If you currently own Bioventus stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financ ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Summary of Bioventus Conference Call Company Overview - **Company**: Bioventus - **Industry**: Medical Technology (Med Tech) - **Annual Revenue**: Over $550 million - **Market Opportunity**: $6 billion across product categories [4][5] Core Business Segments - **Business Segments**: - Pain Treatment - Surgical Solutions - Restorative Therapies - **Market Position**: Category or growth leader in all segments [4] Financial Performance - **Growth Rate**: Expected to grow nearly 2X the weighted average market growth rate despite unfavorable comparisons in the first half of the year [5] - **EBITDA Margin**: Guidance for the year is just over 20%, representing a 100 basis points improvement from the previous year [6] - **Cash Flow Improvement**: Significant progress with cash flow expected to nearly double this year, driven by higher EBITDA, lower interest expenses, and efficient working capital [17][18] Growth Drivers Core Growth Drivers - **Hyaluronic Acid (HA) Therapy**: - Focused on knee osteoarthritis pain with Durolane as a leading product - Strong clinical differentiation and largest dedicated sales force in the space [7][8] - **Bone Graft Substitutes (BGS)**: - Focused on spinal surgery with high single-digit growth [8] - **Fracture Care**: - Restored to growth with double-digit growth in recent quarters, expecting mid-single-digit growth moving forward [9] Expansion Growth Drivers - **Ultrasonics Technology**: - Aimed at changing the standard of care for bone cutting in spine surgery, expected to drive significant growth [10][11] - **International Segment**: - New leadership and plans to aggressively pursue international opportunities, expecting double-digit growth [11] Emerging Growth Drivers - **Peripheral Nerve Stimulation (PNS)**: - Current market size of $200 million in the U.S., expected to exceed $500 million by 2029 [12] - Introduction of StimTrial and Talisman PNS system to enhance treatment options [13] - **Platelet-Rich Plasma (PRP)**: - Current market size of $400 million in the U.S., growing in high single digits, with exclusive distribution agreement for Excel PRP system [14] Strategic Focus - **Value Creation**: - Combination of above-market growth and peer-leading gross margin allows for margin expansion while investing in future growth drivers [16][20] - **Cash Flow and Debt Management**: - Expected leverage to drop below 2.5x, providing optionality for capital deployment [18][19] Conclusion - **Future Outlook**: - Bioventus aims to become a $1 billion high-growth, high-profit, high-cash flow company focused on patient recovery and quality of life [20]

Financial Performance & Growth - The company reported Last Twelve Months (LTM) global proforma revenue of $564 million[7] - The company is experiencing above-market revenue growth, with eight quarters of mid-single-digit or higher growth[8] - The company's organic growth is projected at 7% in 2025[12] - The company's Adjusted EBITDA margin is expected to increase from 13.4% in 2022 to 20.2% in 2025[14] - Cash from Operations is projected to nearly double from 2024 to 2025[19] Market & Strategy - The company operates in a $6.4 billion addressable market[7] - The company has a diversified portfolio in large and growing markets, including Pain Treatments, Surgical Solutions, and Restorative Therapies[8, 6] - The company is focused on margin expansion by leveraging mid-70s gross margin and cost efficiencies[8, 24] - The company aims to increase EBITDA and cash flow to continue reducing leverage[8] Future Outlook - The company projects a net leverage ratio of less than 2.5x by the end of 2025[27] - The company anticipates a free cash flow yield of approximately 60% in 2025[27]

If you like to see more ideas, please subscribe to the premium service "Value in Corporate Events" here and try the free trial. In this service we cover major earnings events, M&A, IPOs and other significant corporate events with actionable ideas. Furthermore, we provide coverage of situations and names on request!In the spring of 2022, I offered some thoughts after an active first year in the case of Bioventus ( BVS ) . After being hyperactive on the dealmaking front, there were many moving parts into 2022 ...

Core Points - Bioventus Inc. will present at the Piper Sandler Healthcare Conference on December 3, 2025, at 10:10 a.m. ET [1] - A live webcast of the presentation will be available on the company's website, with a replay option following the event [2] Company Overview - Bioventus is a global leader in innovations for active healing, providing clinically proven and cost-effective products that facilitate quick and safe healing [3] - The company's mission focuses on helping patients resume and enjoy active lives through its offerings in Pain Treatments, Restorative Therapies, and Surgical Solutions [3] - Bioventus emphasizes high quality standards, evidence-based medicine, and strong ethical behavior, positioning itself as a trusted partner for physicians worldwide [3]

Financial Data and Key Metrics Changes - Third quarter revenue reached $139 million, representing an 8% organic growth, which is an acceleration of over 200 basis points compared to the first half of the year [5][14] - Adjusted EBITDA increased by 13% to $27 million, with an adjusted EBITDA margin expanding by over 200 basis points to 19% [10][15] - Adjusted earnings per diluted share were $0.15, a 200% increase compared to the prior year [11][17] Business Line Data and Key Metrics Changes - Pain Treatments revenue grew 6% in Q3, driven by strong volume growth of Durolane and recent account wins [16] - Surgical Solutions revenue increased by 9%, supported by growth in Ultrasonics and improved awareness of the value proposition [16] - Restorative Therapies revenue declined by 29% due to the divestiture of the Advanced Rehabilitation Business, but organic growth was 11% excluding this impact [16] - International segment revenue decreased by 4%, while organic growth climbed 10% [16] Market Data and Key Metrics Changes - The U.S. market for peripheral nerve stimulation (PNS) is expected to exceed $500 million by 2029, growing above 20% annually [8] - The company anticipates double-digit organic growth in its international segment for 2025, supported by new leadership and market expansion opportunities [16] Company Strategy and Development Direction - The company aims to become a $1 billion high-growth, high-margin, high-cash flow entity, focusing on above-market revenue growth, profitability expansion, and cash flow generation [12] - Key growth drivers include PNS and platelet-rich plasma (PRP) technologies, which are expected to contribute at least 200 basis points of profitable growth in 2026 [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in maintaining guidance for 2025, projecting organic revenue growth of 6%-8% and adjusted EBITDA of $112 million-$116 million [19] - The company is optimistic about growth opportunities in 2026, particularly in PNS, ultrasonics, and international markets, but refrained from providing specific guidance for that year [40][41] Other Important Information - The company absorbed over $2.5 million in unplanned impacts from foreign exchange rate movements [15] - Cash flow from operations totaled $30 million, nearly tripling compared to the prior year, with a cash conversion ratio of over 100% [11][18] Q&A Session Summary Question: Update on pain growth and Durolane performance - Management noted that Durolane led the growth in the pain business, supported by strong sales and clinical differentiation [24][26] Question: Acceleration in surgical business for Q4 - Management indicated that the surgical business, particularly bone graft substitutes, is expected to see continued growth due to strong distributor support and clinical value [27][28] Question: Competitive positioning of Talisman - Management emphasized the importance of scaling the commercial organization and increasing market awareness for the Talisman offering [31] Question: Ultrasonics penetration in spine opportunities - Management highlighted the need for increased awareness and medical education efforts to drive penetration in the spine market [33] Question: Guidance philosophy and expectations for 2026 - Management maintained guidance for 2025 and expressed excitement about growth opportunities in 2026, but did not provide specific guidance for that year [39][40]

Financial Performance - Third quarter revenue was $139 million, comparable to the prior year, with organic growth of 8%[13, 28] - GAAP net income was $3 million, compared to a net loss of $5 million in the prior year[23, 28, 29] - Adjusted EBITDA increased by 13% to $27 million, with Adjusted EBITDA margin expanding by over 200 basis points[23, 28] - Cash from operations nearly tripled for the quarter and is up 88% year-to-date[23] - Adjusted Gross Margin increased 50 basis points due to improved product mix[37] - Adjusted Net Income nearly tripled due to increased gross margin, decreased operating expenses, and decreased interest expense[44] Segment Performance - Pain Treatments revenue grew by 6% to $67 million, driven by strong Durolane volume growth[30, 31, 36] - Surgical Solutions revenue increased by 9% to $50 million, with growth in Bone Graft Substitutes[32, 33, 36] - Restorative Therapies revenue declined by 29% to $21 million due to the divestiture of the Advanced Rehabilitation Business, but EXOGEN grew by 11%[34, 35, 36] Strategic Initiatives - The Peripheral Nerve Stimulation (PNS) market is estimated at approximately $200 million in the U S, expected to exceed $500 million by 2029, with annual growth above 20%[20] - The company expects PNS and PRP to provide at least 200 basis points of profitable growth in 2026[22] Financial Outlook - The company reaffirmed its 2025 financial guidance, with net sales expected to be in the range of $560 million to $570 million, representing organic growth of 6% to 8%[46] - Adjusted EBITDA is projected to be in the range of $112 million to $116 million, and Adjusted Earnings Per Share in the range of $0 64 to $0 68[46]

Financial Performance - Third quarter 2025 worldwide revenue reached $138.7 million, reflecting an 8.2% organic growth, while reported revenue declined 0.2% from $139.0 million in the prior-year period due to the divestiture of the Advanced Rehabilitation Business[4] - Net income attributable to Bioventus Inc. was $3.2 million, a significant improvement from a net loss of $5.2 million in the prior-year period[5] - Adjusted EBITDA for the third quarter was $26.6 million, up 12.9% from $23.6 million in the prior-year period, with an Adjusted EBITDA margin of 19.2%, expanding 220 basis points from 17.0%[6] - Non-GAAP earnings per diluted share increased 200% to $0.15, compared to $0.05 in the prior-year period, driven by improved operating profitability and lower interest expense[7] - Cash from operations increased 192% to $30.1 million[8] - For the full year 2025, the company expects net sales between $560 million and $570 million, reflecting organic growth of approximately 6.1% to 8.0%[18] - Adjusted EBITDA guidance for 2025 is set at $112 million to $116 million, indicating a 100 basis points increase in Adjusted EBITDA Margin compared to 2024[18] Product Development and Launches - The company launched the XCELL PRP System in the U.S. market, designed for customization and efficiency in delivering high platelet count[18] - A limited launch of StimTrial and TalisMann for chronic pain management has been initiated, utilizing PNS products for non-opioid relief[18] Debt and Financing - The company entered into a new Credit Agreement for a $300 million term loan and $100 million revolving credit facility, providing over $2 million in annual interest expense savings[18] Revenue and Profitability Trends - Net sales for the three months ended September 27, 2025, were $138.651 million, a slight decrease of 0.2% compared to $138.964 million for the same period in 2024[25] - Gross profit for the nine months ended September 27, 2025, was $279.375 million, down from $285.570 million in the same period of 2024, reflecting a decrease of approximately 2.5%[25] - Operating income for the three months ended September 27, 2025, was $11.252 million, compared to an operating loss of $3.647 million for the same period in 2024[25] - Net income attributable to Bioventus Inc. for the three months ended September 27, 2025, was $3.155 million, a recovery from a net loss of $5.165 million in the same period of 2024[25] Assets and Liabilities - Total current assets increased to $280.901 million as of September 27, 2025, from $275.610 million as of December 31, 2024, representing a growth of approximately 1.0%[23] - Total liabilities decreased to $494.338 million as of September 27, 2025, down from $542.352 million as of December 31, 2024, indicating a reduction of about 8.8%[23] - Cash and cash equivalents increased to $42.164 million as of September 27, 2025, compared to $41.582 million as of December 31, 2024[23] Research and Development - Research and development expenses for the nine months ended September 27, 2025, were $9.106 million, down from $10.680 million in the same period of 2024, a decrease of approximately 14.7%[25] Stockholder Equity - Total stockholders' equity attributable to Bioventus Inc. increased to $166.096 million as of September 27, 2025, from $147.940 million as of December 31, 2024, reflecting an increase of approximately 12.3%[23] Cash Flow and Operating Activities - Net cash from operating activities for the nine months ended September 27, 2025, was $36,705 million, up from $19,473 million in the prior year, reflecting a 88.5% increase[27] - The company experienced a change in working capital that resulted in a positive cash flow of $10,677 million for the three months ended September 27, 2025, compared to a negative change of $458 million in the same period last year[27] - Cash and cash equivalents at the end of the period were $42,164 million, slightly down from $43,074 million at the end of the same period in 2024[27] Non-GAAP Measures - The company reported a non-GAAP net income of $13,429 thousand for the three months ended September 27, 2025, compared to a net loss of $5,848 thousand for the same period in 2024[49] - Non-GAAP gross margin for the nine months ended September 27, 2025, was 75.6%, indicating strong operational efficiency[49] Future Outlook - The company expects continued growth in adjusted EBITDA and net income for the upcoming quarters, driven by strategic initiatives and market expansion efforts[49]

Group 1 - The article does not provide any specific content related to a company or industry [1]